

EDITORIAL COMMENT

# Cerebral Embolic Protection in Catheter-Based Mitral Interventions

## Research or Clinical Tool?\*

Nicolas M. Van Mieghem, MD, PhD, Lennart van Gils, MD



**T**ranscatheter MitraClip (Abbott Vascular, Santa Clara, California) implantation has emerged as the single catheter-based technique for mitral valve repair with global adoption. Worldwide, an estimated 25,000 patients have been treated with the MitraClip so far. Typically, the incidence of major stroke after surgical mitral valve repair or replacement is similar to what is seen after surgical aortic valve replacement, and varies between 1% and 5% (1-3). In the only randomized trial comparing MitraClip with mitral valve repair/replacement, major stroke rate at 30 days was 1% after MitraClip and 2% after mitral valve surgery (4). The EVEREST (Endovascular Valve Edge-to-Edge Repair Study) 2 predominantly enrolled patients with degenerative mitral valve disease (4). In the larger European MitraClip registries, patients had more functional mitral regurgitation (MR). The clinically major stroke rate after clipping appeared to be negligible and <1%: 0.7% in 560 patients in the ACCESS EU (ACCESS-Europe A Two-Phase Observational Study of the MitraClip System in Europe) trial, and 0% in 1,064 patients in the German TRAMI (Transcatheter Mitral Valve Interventions) Registry (5,6).

Important lessons were learned after a decade of controversy about stroke rates in patients undergoing surgical or catheter-based aortic valve replacement. The randomized PARTNER (Placement of Aortic Transcatheter Valve) I trial seemed to suggest that

the less-invasive transcatheter aortic valve replacement (TAVR) was associated with a higher neurological event rate compared with surgical aortic valve replacement; yet, the randomized U.S. CoreValve high-risk study refuted these findings (7,8). Interestingly, the involvement of competent authorities like the U.S. Food and Drug Administration, efforts by the Valve Academic Research Consortium to determine uniformity in endpoint definitions and trial design, and the advent of embolic protection devices have scrutinized research on neurological events in the field (9). Neurology experts are now involved in most important TAVR trials and assess all enrolled patients undergoing valve replacement before and after the procedure. This scrutiny has revealed more (subtle) neurological changes in significantly more patients. Indeed, new neurological events were detected in 15% of patients in the control arm of the randomized DEFLECT III (A Prospective, Randomized Evaluation of the TriGuard HDH Embolic Deflection Device During TAVI) trial and in 17% of patients undergoing surgical aortic valve replacement in the DeNOVO (Determining Neurologic Outcomes from Valve Operations) prospective cohort study (10,11). Diffusion-weighted magnetic resonance imaging (MRI) studies and histopathology studies have revealed signs of cerebral embolization in over 80% of patients undergoing TAVR (12-14).

SEE PAGE 171

\*Editorials published in *JACC: Cardiovascular Interventions* reflect the views of the authors and do not necessarily represent the views of *JACC: Cardiovascular Interventions* or the American College of Cardiology.

From the Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands. Dr. Van Mieghem has received research grants from Claret Medical Inc., Medtronic, Edwards Lifesciences, St. Jude Medical, and Boston Scientific. Dr. van Gils has reported that he has no relationships relevant to the contents of this paper to disclose.

Deflecting and filter-based embolic protection devices (EPDs) are being intensely studied in the field of TAVR, and not surprisingly, interest for EPD also emerges in the MitraClip space (15). In this issue of *JACC: Cardiovascular Interventions*, Frerker et al. (16) study the use of filter-based embolic protection in patients undergoing MitraClip implantation.

The Sentinel EPD (Claret Medical Inc., Santa Rosa, California) provides filter protection for 3 of 4 arterial contributors to the brain. The filters can be retrieved and microscopically analyzed. Fourteen patients with severe MR were included in the analysis. Most patients had functional MR and concomitant permanent atrial fibrillation. Debris was detected in all patients. Acute thrombus and foreign body material was most common. The presence of acute thrombus is remarkable, especially since optimal per-procedural anticoagulation with heparin was achieved (mean activated clotting time  $289 \pm 48$  s). This raises the question about the etiology of this acute clot formation: device manipulations in the left side of the heart but also the use of the filters themselves may be pro-thrombogenic. Furthermore, procedure times exceeding 90 min may result in transient suboptimal anticoagulation and, thus, promote acute thrombus formation. In fact, MitraClip procedure/device time has previously been associated with more new brain lesions by MRI (17). Conversely, the presence of organizing thrombus in the filters may be associated with the high prevalence of atrial fibrillation that hypothetically may have accounted for the organized thrombus surrounding the mitral valve apparatus. The authors describe the foreign body material as nonpolarizable basophilic material consistent with hydrogel, most probably from the hydrophilic coating of the transseptal sheath, guide delivery catheter, or the clip delivery system and thus inherent to the procedure. In more than one-half of the patients, mitral valve and atrial tissue was found. The authors do not discuss the effect of the number of attempts to grasp both mitral leaflets to eventually close and deploy the MitraClip. One can only wonder whether more attempts could dislodge more tissue. Furthermore, would there be a difference between functional and degenerative MR, with the latter displaying an excess of tissue? The finding that the use of more clips seemed to generate larger debris is intriguing.

In comparison to what typically is captured after TAVR, debris seemed smaller with MitraClip:  $295 \mu\text{m}$

(interquartile range: 104 to  $509 \mu\text{m}$ ) versus  $1 \mu\text{m}$  (interquartile range: 0.6 to 1.5 mm) (14). Smaller particle size may reflect the preponderance of functional MR in this study with structurally normal mitral valve leaflets. Similarly, this may explain why no calcium particles were captured. This contrasts with the yield after TAVR, with tissue debris in two-thirds of all patients including amorphous calcium.

The current data are complementary to the recent brain MRI study by Blazek et al. (17), in which a median of 3 new brain lesions were found in 85% of patients after MitraClip.

Given the (very) low clinical stroke rates after MitraClip, purists may claim that EPDs are useless in this setting. Others may argue that even subclinical brain infarcts may not be harmless and may increase the risk for dementia and neurocognitive deterioration in the long run (18). Future research efforts may focus on: 1) the difference in cerebral embolization between functional and degenerative MR; 2) the effect of EPD on new brain lesions by MRI; 3) cerebral embolization burden with transcatheter mitral valve implantation, which intuitively seems more traumatic than MitraClip and may thus dislodge more tissue debris; and maybe most importantly, 4) the effect of new brain lesions after structural heart interventions on immediate and late neurocognitive performance.

In aggregate, cerebral embolization seems ubiquitous with structural left-sided heart interventions. The study by Frerker et al. (16) provides complementary histopathological evidence to prior brain imaging data. Only the future can tell whether filter-based cerebral embolic protection is merely an interesting research tool or an essential clinical accessory for superior procedural (brain) safety.

---

**REPRINT REQUESTS AND CORRESPONDENCE:** Dr. Nicolas M. Van Mieghem, Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, Room Bd 171, 's Gravendijkwal 230 3015 CE Rotterdam, the Netherlands. E-mail: [n.vanmieghem@erasmusmc.nl](mailto:n.vanmieghem@erasmusmc.nl).

---

## REFERENCES

1. Acker MA, Parides MK, Perrault LP, et al. Mitral valve repair versus replacement for severe ischemic mitral regurgitation. *N Engl J Med* 2014;370:23–32.
2. O'Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. *Ann Thorac Surg* 2009;88:S23–42.
3. Shahian DM, O'Brien SM, Filardo G, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3—valve plus coronary artery bypass grafting surgery. *Ann Thorac Surg* 2009;88:S43–62.
4. Feldman T, Foster E, Glower DD, et al., for the EVEREST II Investigators. Percutaneous repair or surgery for mitral regurgitation. *N Engl J Med* 2011;364:1395–406.
5. Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. *J Am Coll Cardiol* 2013;62:1052–61.
6. Schillinger W, Hunlich M, Baldus S, et al. Acute outcomes after MitraClip therapy in highly aged patients: results from the German Transcatheter Mitral Valve Interventions (TRAMI) registry. *EuroIntervention* 2013;9:84–90.

7. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med* 2010;364:2187–98.
  8. Popma JJ, Adams DH, Reardon MJ, et al., for the CoreValve United States Clinical Investigators. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol* 2014;63:1972–81.
  9. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *J Am Coll Cardiol* 2012;60:1438–54.
  10. Messe SR, Acker MA, Kasner SE, et al., for the Determining Neurologic Outcomes from Valve Operations (DeNOVO) Investigators. Stroke after aortic valve surgery: results from a prospective cohort. *Circulation* 2014;129:2253–61.
  11. Lansky AJ, Schofer J, Tchetché D, et al. A prospective randomized evaluation of the TriGuard™ HDH embolic DEFLECTION device during transcatheter aortic valve implantation: results from the DEFLECT III trial. *Eur Heart J* 2015;36:2070–8.
  12. Fanning JP, Walters DL, Platts DG, Eeles E, Bellapart J, Fraser JF. Characterization of neurological injury in transcatheter aortic valve implantation: how clear is the picture? *Circulation* 2014;129:504–15.
  13. Van Mieghem NM, Schipper ME, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. *Circulation* 2013;127:2194–201.
  14. Van Mieghem NM, El Faquir N, Rahhab Z, et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. *J Am Coll Cardiol Interv* 2015;8:718–24.
  15. Van Gils L, Baumbach A, Himbert D, Lansky AJ, Vahanian A, Van Mieghem NM. Tools and techniques—clinical: embolic protection devices in transcatheter aortic valve implantation. *EuroIntervention* 2015;11:247–8.
  16. Frerker C, Schlüter M, Sanchez OD. Cerebral protection during MitraClip implantation: initial experience at 2 centers. *J Am Coll Cardiol Interv* 2016;9:171–9.
  17. Blazek S, Lurz P, Mangner N, et al. Incidence, characteristics and functional implications of cerebral embolic lesions after the MitraClip procedure. *EuroIntervention* 2015;10:1195–203.
  18. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med* 2003;348:1215–22.
- 
- KEY WORDS** aortic stenosis, cerebral embolic protection, TAVR